InnoCare licensing deal flops due to lack of upfront cash
The Chinese biotech agreed to sell some of the rights to its flagship drug for a sum that could exceed $2 billion but investors were unhappy with the fine print…
Recent Articles
InnoCare licensing deal flops due to lack of upfront cash
9969.HK
688428.SHG
RELATED ARTICLES
-
InnoCare hits profit milestone, enters new phase with global expansion, strong pipeline
9969.HK688428.SHG -
RemeGen scores out-licensing triple play with AbbVie deal
9995.HK688331.SHG
- Mega licensing deal lifts 3SBio profits but core sales slip
- A healthy return: drug spin-off nets Keymed up to $320 million
- Big deal, bigger doubts: CSPC slides after $18.5 billion pact
- Jacobio Pharma poised to turn a profit from precision cancer drugs
